Standard BioTools Sells Two Businesses For $10.5 Million, Leaving An $18.6 Million Lease Asset At Risk

The sales' $5.5 million and $5.0 million prices may trigger a material write-down of a lease asset, while the lease payments stay.

Share
Standard BioTools Sells Two Businesses For $10.5 Million, Leaving An $18.6 Million Lease Asset At Risk

Standard BioTools, which makes research instruments and consumables for studying proteins and genes, agreed to sell its mass cytometry business for $5.5 million and its microfluidics business for $5.0 million, and its quarterly report warns the sales could force a material write-down of a South San Francisco lease asset. The company is selling the units ahead of a planned merger with Treeline Biosciences.

An $18.6 million asset tied to the sales

The office lease's right-of-use asset stood at $18.6 million on September 30. The filing says the asset's value partly hinges on cash generated by the two units being sold; the company found no impairment as of that date.

After the sales, though, it is "reasonably possible" that the company will book an impairment, "which could be material." Any such write-down would not reduce what the company owes under the lease, which runs to April 2030.

The company vacated the space on December 31, 2025. After a sublease signed since quarter-end covering the last floor, which is expected to bring about $2.1 million of fixed payments through April 2030, it now subleases the whole premises. Subtenant payments fall short of what the company owes, so it anticipates paying out net cash on the premises until the lease ends.

Two buyers, a swapped deal and a fee

The mass cytometry buyer is Element Biosystems, a wholly owned subsidiary of GMT Venture Partners, paying $5.5 million in cash. That sale needs stockholder approval and completion of the Merger.

Element replaced an earlier deal. In the prior quarterly report, Multiplex Bio was to buy the unit for up to $10.0 million, mostly via a promissory note with no cash at closing. On September 30 the board judged GMT's offer superior, and the Multiplex deal ended with a $1.5 million termination fee, of which GMT paid $1.0 million. The company may have to refund that amount in certain circumstances.

Biomark Scientific, formed by healthcare investor ARCHIMED, bought the microfluidics unit on Tuesday for $5.0 million, with customary post-closing adjustments to come.

What shareholders get from the proceeds

Under the Merger, existing stockholders are expected to hold about 16% of the combined company. They are also due one contingent value right per share, paying out in stock based on net proceeds from the two legacy businesses and other sources, capped at 76.0 million shares. The company says there is no assurance any payments will be made.

The company reported $559.4 million in cash and investments at September 30, after receiving $388.2 million at the January 2026 close of its SomaScan sale to Illumina, which included $25.0 million of contingent consideration.

Stockholders vote on the Merger and the mass cytometry sale at a special meeting on November 19.

The company targets a Merger close in the fourth quarter of 2026, after the November 19 vote.

Sources

More on Standard BioTools

All Standard BioTools (LAB) coverage →